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Abstract
Background: The use of biological annotation such as genes and pathways in the analysis of gene expression data has 
aided the identification of genes for follow-up studies and suggested functional information to uncharacterized genes. 
Several studies have applied similar methods to genome wide association studies and identified a number of disease 
related pathways. However, many questions remain on how to best approach this problem, such as whether there is a 
need to obtain a score to summarize association evidence at the gene level, and whether a pathway, dominated by 
just a few highly significant genes, is of interest.
Methods: We evaluated the performance of two pathway-based methods (Random Set, and Binomial approximation 
to the hypergeometric test) based on their applications to three data sets of Crohn's disease. We consider both the 
disease status as a phenotype as well as the residuals after conditioning on IL23R, a known Crohn's related gene, as a 
phenotype.
Results: Our results show that Random Set method has the most power to identify disease related pathways. We 
confirm previously reported disease related pathways and provide evidence for IL-2 Receptor Beta Chain in T cell 
Activation and IL-9 signaling as Crohn's disease associated pathways.
Conclusions: Our results highlight the need to apply powerful gene score methods prior to pathway enrichment tests, 
and that controlling for genes that attain genome wide significance enable further biological insight.
Background
In order to increase the power of genome wide associa-
tion studies (GWAS) to identify the biological mecha-
nisms underlying complex disease, the field is leveraging
many methodological advances on the analysis of gene
expression microarray data. In a standard gene expres-
sion analysis, measured probe intensities are first sum-
marized to estimate the expression level of a gene, and
these genes are often ranked according to the statistical
evidence, such as derived from T or moderated T-tests, of
their differential expression between conditions. The
genes at the top of the list are then considered for follow-
up studies, but it is a nontrivial decision on how many of
these genes to pursue for further investigation. Biological
annotation is often incorporated to facilitate this deci-
sion. It is unclear that using annotation information in
the analysis of GWAS data would attain the same
increase in power seen in gene expression analysis
because functional and genetic variation have not been
found to exhibit the same clustering within pathways as
gene expression [1]. However, Elbers et al. [2] conclude
that disease related genes may be functionally related and
grouped in pathways due to the small number of path-
ways that are assumed to contribute to the development
of complex diseases. Additionally, several studies have
reported pathway analysis results for GWAS [3-6] show-
ing the power of this approach to identify disease associ-
ated pathways.
There are a number of statistical issues to address in
implementing pathway analysis. First and foremost, a
decision has to be made on which collection of pathways
to consider and which gene annotation to use in the anal-
ysis. Second, the boundary regions need to be defined
around a gene. Third, a statistical method needs to be
selected 1) to compute a gene level measure of associa-
tion to the disease status (a gene score) if such a gene-
based summary is needed, and 2) to identify pathways
either enriched for association signals or highly predic-
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Page 2 of 9tive of disease status. Additional issues involve handling
genes in linkage disequilibrium and genes residing in
multiple pathways.
Several association tests can be used to calculate gene
level scores. The most commonly used method is to iden-
tify the SNP with the lowest p-value and then allow for
multiple comparisons through permutation, however, it
is not the most powerful [7,8]. Our simulation study has
shown that PCA regression is more powerful than the
best scoring SNP when including the possibility of multi-
ple causal SNPs of varying allele frequencies [8]. These
gene scores are then used to determine which pathways
are enriched in the data set. One method to determine
pathway enrichment is with contingency table tests: chi-
square test, Fisher's Exact test, or a binomial test [see 9
for a review]. Another method is described by Newton et
al. [10], it incorporates the use of random-set methods to
determine the enrichment of genes in a pathway. These
methods use the same null hypothesis as the contingency
table methods above, but determine their significance by
creating an empirical distribution of a pathway's signifi-
cance by using random sets of genes. (Please see Cantor
et al. [11] for a review of statistical methods.)
Here we use several analysis methods on two well pub-
licized datasets of Crohn's disease. We apply two meth-
ods to compute gene level scores as well as two different
methods to identify pathways associated with the disease.
We also investigate the impact of IL23R to the pathway
results by two methods. First, we remove IL23R from the
list of measured genes and rerun the analysis. Second, we
condition the disease status on IL23R and use the residu-
als as the outcome variable. IL23R was first identified and
replicated in the datasets used in our analysis and is the
highest ranking known gene in each dataset. By removing
IL23R, we can evaluate each method's ability to identify
disease related pathways after the removal of major
genetic contributors. Lastly, we explore our pathway
results to identify other genes implicated in the disease.
Results
Gene Scores
The top ten genes for each dataset using PCA regression
contain known Crohn's related genes. In the Jewish (J)
dataset IL23R, PHOX2B, IL13, and MAST3 were ranked
3rd, 4th, 8th, and 9th, respectively (Table 1). IL23R and
NOD2 were ranked first and second, respectively in the
non-Jewish (NJ) dataset (Table 1). And, IL23R, IRGM,
NOD2, PTPN2 were ranked 2nd, 4th, 7th and 10th in the
Wellcome Trust (WTCCC) dataset (Table 1). Interest-
ingly, after variation explained by IL23R was removed
from the data and gene scores were recalculated, the top
genes remained consistent. Note that for the pathway
enrichment analysis, all genes with SNPs mapped within
their boundaries were used.
Table 1: Top 10 ranking genes for each dataset using 
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The RS method applied to gene scores calculated from
PCA regression identified 38, 14, and 7 pathways as sig-
nificant for the WTCCC, J, and NJ datasets, respectively.
Two pathways were common to all three datasets, ten
were in common only between the WTCCC and J data-
sets, one between only WTCCC and NJ. The pathways in
common across all datasets are BioCarta's IL-2 Receptor
Beta Chain in T Cell Activation Pathway and GenMAPP's
IL-9 signaling pathway (Table 2). All significant pathways
are shown in Additional file 1 Table S1. Genes for each
pathway are listed in the Additional file 2 Tables S3 and
S4. Applying the BIN enrichment method to the same
data, 36 pathways are significant for WTCCC, 6 for J, and
2 for the NJ. Of the 36 pathways in the WTCCC, 27 are in
common to those identified by RS, 4 of the 6 for the J and
zero of the NJ are in common. In the J dataset, the adipo-
genesis pathway as well as IL-22, -7 and NF-κB pathways
were identified. Pathways found using the BIN method
are listed in Additional file 3 Table S2.
The same enrichment methods were applied after dis-
ease status had been conditioned on IL23R. In the
WTCCC dataset 32 pathways were significant by the RS
method, 21 of the 32 were in common to the significant
pathways above which included IL23R. The BIN method
determined 17 pathways significant, 10 of which were in
common to those identified when IL23R was included.
Removing the variation of IL23R had a larger impact on
the J and NJ datasets than WTCCC. Using RS, only three
pathways were significant in the J population, one of
which was significant previously. The BIN method deter-
mined two as significant, none matching the uncondi-
tioned analysis. In the NJ data, the RS method found four
pathways significant, none in common to pathways when
IL23R variation was included. The BIN method found no
pathways significant following the removal of IL23R.
There were no common pathways across the three data-
sets using either RS or BIN; however, BioCarta's 'Cells
and Molecules Involved in Local Acute Inflammatory
Response' was significant in both the J and NJ datasets
with RS. See Additional file 1 Table S1.
If IL23R is removed from the list of measured genes and
the analysis is performed, the significant pathways are
generally the same as those when IL23R is included.
Using RS, 32 pathways are significant in WTCCC, 28 of
which overlap with pathways identified when IL23R is
included; six are significant in J, two overlapping those
including IL23R; and five in the NJ where two overlap sig-
nificant pathways found using IL23R. The BIN results
were more consistent to pathways identified using IL23R.
Figure 1 shows the overlap for each method.
IL23R Effect
IL23R is the highest ranked known Crohn's disease gene
in each of the data sets and it is present in 29 of the path-
ways used in our analysis. In fact for the RS results, 27 of
the 38 WTCCC significant pathways, 12 of the 14 signifi-
cant J pathways, and three of the seven significant NJ
pathways contain IL23R. Using BIN the influence of
IL23R is reduced; nevertheless, 26 of 36 in WTCCC and
four of six in J significant pathways contained IL23R.
Given that there is overlap in the pathways identified as
significant between the conditioned and unconditioned
and removal of IL23R data (10 in the WTCCC using RS, 4
using BIN) IL23R is not responsible for making all of the
IL23R containing pathways significant. The impact on the
J and NJ data is more dramatic; all IL23R containing path-
ways are no longer significant. When IL23R is simply
removed from the analysis a similar decrease in the num-
ber of identified pathways decreases in the J and NJ.
Given the lack of fluctuation in gene scores following
conditioning in the WTCCC data, we were curious to see
eleven new pathways reaching significance in the condi-
tioned data by RS (Table 2 and Additional file 1 Table S1).
Twenty-one of the 32 significant pathways were in com-
mon to the unconditioned data and represent expected
Crohn's disease pathways: interleukin signaling, B Cell,
and cytokine signaling pathways. The other eleven path-
ways are pathways not previously identified in other path-
way analyses of Crohn's disease. Looking at the genes that
make up these pathways, many are found in more than
one pathway. For example, Wnt signaling genes (WNT3,
WNT3A, WNT9A, WNT9B with p-values 1.8 × 10-3, 3.6
× 10-3, 1.2 × 10-3, and 6.8 × 10-5, respectively) and cal-
cium/calmodulin dependent protein CAMK2G (p-value
2.0 × 10-3) are in four pathways. Interestingly, the WNT
genes above had comparable gene score before and after
conditioning; however, the effect of IL23R was able to
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Pathway Method IL23R status Dataset
IL-9 Signaling RS in WTCCC, J, NJ
IL-2 Receptor Beta Chain in T cell Activation RS in WTCCC, J, NJ
Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through 
the T Cell Receptor pathway
RS,BIN in, out, cond WTCCC
Ahr Signal Transduction Pathway RS in, out, cond WTCCC
Antigen Dependent B Cell Activation pathway RS in, out, cond WTCCC
Bystander B Cell Activation pathway RS in, out, cond WTCCC
Cytokines and Inflammatory Response pathway RS, BIN in, out, cond WTCCC
Erythropoietin mediated neuroprotection through NF-kB pathway RS in, out, cond WTCCC
Hypoxia-Inducible Factor in the Cardiovascular System pathway RS in, out, cond WTCCC
IL 4 signaling pathway RS in, out, cond WTCCC
IL 5 Signaling Pathway RS in, out, cond WTCCC
IL12 and Stat4 Dependent Signaling Pathway in Th1 Development pathway RS in, out, cond WTCCC
IL22 Soluble Receptor Signaling Pathway RS in, out, cond WTCCC
Lck and Fyn tyrosine kinases in initiation of TCR Activation pathway RS, BIN in, out, cond WTCCC
NO2-dependent IL 12 Pathway in NK cells pathway RS, BIN in, out, cond WTCCC
Selective expression of chemokine receptors during T-cell polarization pathway RS in, out, cond WTCCC
Glycerolipid metabolism RS in, out, cond WTCCC
Glycerophospholipid metabolism RS in, out, cond WTCCC
Adipogenesis Human RS, BIN in, out, cond WTCCC
IL-4 signaling pathway RS, BIN in, out, cond WTCCC
Kit Receptor Signaling Pathway RS, BIN in, out, cond WTCCC
TPO Signaling Pathway RS in, out, cond WTCCC
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of significant pathways decreases using both RS and BIN.
Using RS, the significant pathways identified for WTCCC
are by and large the same significant pathways when
IL23R is included in the analysis. These pathways were
primarily made of up cytokine signaling, T-cell, and B-
cell pathways. In the J dataset, only two pathway out of
four overlaps those found using IL23R. All of the path-
ways identified were cytokine pathways. The only path-
way identified by all three methods was
'Glycosphingolipid biosynthesis'. The NJ data had two out
of five significant pathways that overlapped pathways
found when IL23R was included. 'Deregulation of CDK5
in Alzheimer's Disease pathway' was significant in each
method (Table 2). The BIN results identified few path-
ways as well. All identified pathways in the WTCCC and
NJ data overlapped pathways identified using IL23R, the J
identified one pathway, 'Inflammatory Response', that did
not overlap.
Role of Erk5 in Neuronal Survival pathway BIN in, out, cond WTCCC
Transcription factor CREB and its extracellular signals pathway BIN in, out, cond WTCCC
Acetylcholine Synthesis BIN in, out, cond WTCCC
Glycosphingolipid biosynthesis RS in, out, cond J
Deregulation of CDK5 in Alzheimers Disease pathway RS in, out, cond NJ
The table summarizes the significant pathways identified in the three datasets, Wellcome trust Case-Control Consortium (WTCCC), Jewish (J), 
non-Jewish (NJ), that were significant using either method, Random Set (RS) or Binomial (BIN). The table also notes how IL23R was treated in 
the enrichment analysis, included (in), excluded (out), or conditioned upon (cond). The complete list of significant pathways are found in 
Additional Tables 1 and 3.
Table 2: Summary of significant pathways identified (Continued)
Figure 1 Overlap of significant pathways identified by each method (Random Set, Binomial) in each of the datasets (WTCCC, Non-Jewish, 
Jewish). Numbers are equal to number of significant pathways for each analysis: NC = non-conditioned, C = conditioned, NoIL23R = IL23R removed 
from gene list.
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The number of significant pathways identified using the
pathway enrichment methods is larger when the gene
score is calculated with PCA regression compared to the
best scoring SNP within the gene. Table 3 lists the num-
ber of pathways identified as significant for the three data
sets using the BI method on gene scores calculated by
using the normalized, most significant SNP within the
gene as the gene score. This method is the most com-
monly used method for calculating gene scores from
GWAS data. Only five, zero, and two pathways were
enriched using this gene score for the WTCCC, J, and NJ
datasets, respectively. This is compared to 36, 6, and 2
(WTCCC, J, NJ) when the gene scores are calculated
using PCA regression.
Discussion
Over the past few years, GWAS studies have had a large
impact on identifying the determinants of complex dis-
eases, and Crohn's disease has been the focus of many
researchers. Here we used two studies, both of which
implicated novel susceptibility genes for Crohn's disease,
as a basis for identifying biological pathways associated
with the disease. We applied two methods to calculate
gene score association, and three analyses to determine
pathway enrichment. We also evaluated the impact that a
highly associated known disease related gene has on the
identification of enriched pathways.
Previous analyses of Crohn's disease describe an
enrichment of pathways involved in calcium signaling,
Transcription/ChREBP regulation, Immune response
(IL2, IL3, IFN alpha/beta, antigen presentation), lipid
metabolism, and the developmental role of CDK5 in neu-
ronal development [5]. Wang et al. [6] identified enrich-
ment of the IL12 signaling pathway in multiple data sets,
and Holmans et al. [12] found enrichment of the major
histocompatibility complex (MHC), immunological
response, and antigen processing gene ontology catego-
ries. These results were found using the same WTCCC
data set analyzed here. Despite the differences in imple-
mentation across methods (e.g., how SNPs are assigned
to genes, definition of gene boundaries, gene set annota-
tion used, pathway enrichment determination) there are
common themes to the results. The main commonality is
the immune response (interleukin) pathways which rep-
resent the immune system's complex signaling response
to microbial infection and injury, as well as the dysregu-
lated response observed in disease. These are perhaps the
most expected given the association of IL23R and other
pathways ultimately affecting interleukin signaling to
Crohn's disease [13,14]. Our results confirmed the signif-
icance of many of the immune response pathways, and
although IL12 was not our highest ranking pathway as in
Wang et al. [15]; it was found to be significant. Addition-
ally, of the potential Crohn's disease susceptibility genes
suggested by Wang et al. [15], only IL12B obtained a low
gene score (4.67 × 10-3) in our analysis. In our annotation
of IL12 pathways, IFNGR1 had the most significant gene
score (6.82 × 10-7 unconditioned, 5.10 × 10-6 after condi-
tioning). We also confirmed the association of lipid/adi-
pogenesis pathways and CDK5 first proposed by
Torkamani et al. (2007). Our CDK5 enrichment was
found in the non-Jewish dataset, not in the WTCCC. Cal-
cium signaling pathways proposed by Torkamami et al.
[5] were not significant in our analysis. However, RHOA
was responsible for pushing several pathways to signifi-
cance in the WTCCC data. This difference may be due to
a difference in pathway definition. Several MHC genes
were identified as significant in our analysis. Holmes et al.
[12], who looked at the over-representation of GO cate-
gories, detailed several genes in their enriched MHC Go
category as potential Crohn's genes. Our analysis found
HLA-DQA2, HLA-DQB2, HLA-DOB, and HLA-DRA, to
be highly associated with the disease. We did not, how-
ever, have an MHC pathway in our annotation. Lastly, we
identify many of the same pathways as significant as Peng
et al.[4]: IL -2, -3, -4, -6, -12 signaling, Sphingolipid
Metabolism, CDK5, T Cell Receptor, Cytokine and
Inflammation related pathways. In their study, they com-
puted gene scores using the best scoring SNP within a
gene and used Fisher Exact Test and Simes/FDR to iden-
tify significant pathways in several datasets, including
WTCCC. Like our results, the Fisher Exact Test was the
more conservative of the methods used.
Our results identified two pathways (IL-2 Receptor
Beta Chain in T cell Activation, IL-9 Signaling) as signifi-
cant in each dataset with RS, which weights genes by
their p-value. These findings are consistent with known
functional roles of these pathways in intestinal immune
homeostasis. For example, the IL-2 pathway is critical in
T cell activation and regulatory T cell function. As such,
IL-2R-deficient animals develop intestinal inflammation
[16]. Moreover, the IL-9 signaling pathway enhances reg-
ulatory T cell function, Th17 and Th2 differentiation
[17,18], as well as regulating mast cell and goblet cell
function [19-21], all of which are critical in intestinal
immunity. Using BIN, they are only significant in the
WTCCC data. This is likely due to the increase in power
associated with the larger sample size in the WTCCC
dataset compared to the J and NJ datasets. Once variation
from IL23R is removed, these two pathways are no longer
significant in any of the datasets. Interestingly, our
'Autophagy' pathway based on Refseq gene descriptions
was not significant in any dataset using either method.
Our earlier simulation study showed that PCA regres-
sion had more power to identify associations than using
the best scoring SNP within a gene when the association
was due to multiple SNPs within a gene. We created gene
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to each of dataset using a p-value threshold of 0.05. The
comparable number of identified known genes using a
liberal threshold may not be unexpected given that these
genes were originally identified using a single SNP analy-
sis. However, using these gene scores to perform pathway
analysis resulted in quite different results - PCA gene
scores identified more disease related pathways. Given
the success of PCA applied to genes within a gene, we
investigated using PCA applied to all SNP within all
genes of a pathway and then performing the regression.
The results did not identify any enriched pathways.
The difference in the number of significant pathways
identified between the RS and BIN methods illustrates
the impact that highly significant genes within a pathway
can have on pushing a pathway to becoming significant.
Weighting genes by their significance may increase power
to identify pathways, but highly significant genes would
have been found with a single SNP analysis and their
annotated pathways would have warranted follow-up
without a pathway analyses. Given that IL23R was signifi-
cant in each of the datasets, we evaluated the impact of
IL23R on the resulting pathway analysis. Removing this
variation had a large impact on the smaller J and NJ data-
sets; it resulted in removing all interleukin-related path-
ways from significance. There were, however, a few
remaining pathways that maintained their significance
and contain genes that have an implicated role in Crohn's
disease. The ability of the Jewish population to maintain
some power compared to the non-Jewish population
could be explained by the higher prevalence of Crohn's
disease observed in the Ashkenzi Jewish population com-
pared to similar non-Jewish populations. The WTCCC
dataset was significantly larger than either the J or NJ
datasets, and provided more power to identify disease
related pathways. Even when conditioned on IL23R,
many interleukin pathways remained significant. Of
interest, though, is that removing IL23R variation allowed
other pathways to become significant that were not previ-
ously: two different annotations of WNT signaling path-
ways became significant. These results match previously
published IBD gene expression studies which found sig-
nificantly increased expression of seven WNT genes in
IBD patients compared to non-IBD controls [22].
Conclusions
While many issues regarding pathway analysis in GWAS
remain (which annotation collection is more appropriate,
how many base pairs around a gene should be included to
account for linkage disequilibrium when calculating gene
scores), its application has identified appropriate disease
related pathways in multiple studies. Here, we show the
impact of using a less powerful gene score method as
input to gene set enrichment in GWAS as well as the
effect a single highly significant gene can have on the
identified pathways. Pathway enrichment methods that
do not incorporate a gene score, however, may be less
biased towards pathways that contain genes near highly
significant SNPs. Importantly, regardless of the pathway
method used, removing the variation explained by signif-
icant genes did not eliminate the ability of pathway
enrichment methods to identify disease related genes.
Methods
We consider three Crohn's disease data sets obtained
from two previously published studies. Duerr et al.[13]
performed the first case-control GWAS for inflammatory
bowel disease. This study included two subject cohorts,
Jewish and non-Jewish. The non-Jewish cohort consisted
of 567 cases and 571 controls; whereas the Jewish cohort
included 401 cases and 433 controls. Each subject was
genotyped using Illumina's HumanHap300 BeadChip.
This study identified a number of independent associa-
tions in the IL23R gene region for both Crohn's disease
and ulcerative colitis, in addition to confirmation of the
previously identified Crohn's disease associations with
NOD2. Following this finding, the Wellcome Trust Case
Control Consortium [23] published GWAS results of
seven complex diseases including Crohn's disease. For
each disease, the Consortium enrolled 2,000 subjects
with the disease but used a common set of 3,000 controls
to test for association. Their control group contained
1,500 individuals from two sources - the 1958 British
Birth Cohort and blood donors from the UK blood Ser-
vices. All subjects in this study were genotyped using the
Affymetrix GeneChip Human Mapping 500 K Array Set.
We apply each method to Duerr et al's Jewish (J), non-
Jewish (NJ), and Welcome Trust Case Control Consor-
tium's (WTCCC) inflammatory bowel/Crohn's disease
data sets.
We included only SNPs with a missing rate <10%, that
were in Hardy Weinberg equilibrium (chi-square p-value
greater than 0.001), and had a minor allele frequency
greater than 1% in each data set. Subjects with greater
than 6% missing values were removed from the analysis.
Table 3: Number of significant pathways identified using 
PCA regression and Best scoring SNP within a gene to 
calculate gene level scores
Pathway 
method
Data set PCA Best Scoring SNP
Binomial Jewish 6 0
Non-Jewish 2 2
WTCCC 36 5
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annotation downloaded from NCBI http://www.ncbi.
nlm.nih.gov/. A SNP was considered 'in' a gene if it was
located within the gene boundaries plus/minus 10 kb.
There were SNPs that did not get mapped to a gene in
each dataset. Our pathway annotation was compiled
from three public databases: KEGG [24], GenMAPP [25],
and BioCarta [26]. We created one additional pathway by
searching Refseq annotation gene descriptions for the
word 'autophagy'. Such a pathway is of interest because
autophagy genes have been implicated in Crohn's disease
[27]. There were a total of 565 pathways consisting of a
total of 5,464 unique genes; note that one gene may occur
in more than one pathway. The median number of genes
per pathway is 28 genes, and pathways averaged 47 genes
in size.
We calculated each gene level score using SNPs
mapped to genes, where the SNPs were converted from
character (A, T, C, G) into the count of the minor allele.
Principal component analysis (PCA) was applied to the
correlation matrix of the gene's SNPs, and then the com-
ponents that explained at least 85% of the variation were
used as explanatory variables in the regression to explain
disease status. The p-value from this multiple regression
is the gene score. For comparison purposes, gene level
scores using the SNP with the lowest p-value within the
gene boundaries were calculated as well. Permutation of
the case control status was used to standardize the p-
value within each gene.
We identified disease associated pathways using two
methods. The first method was the binomial test (BIN),
an approximation to the Fisher's Exact Test. The binomial
approximation has been widely used in gene expression
studies [28] and is computationally faster than Fisher's
Exact Test. Genes were significant if their gene scores
were less than 0.05. The test statistic of our second
method, the random set method (RS), weighs each gene
by its p-value to determine enrichment. Specifically, our
RS method's test statistic is equal to the negative of the
sum of the log p-values for each gene assigned to the
pathway [10]. An approximate FDR was calculated for
each method using a two step procedure. Step one - gene
scores were computed using 1000 permutations of dis-
ease status. Step two - for each set of permuted gene
scores, pathway enrichment was calculated using 10,000
permutations of the gene scores. The approximate false
discovery rate was calculated by averaging the number of
pathways with a p-value less than that obtained using real
data. Pathways with an estimated FDR less than 0.01 are
reported.
We evaluate the effect of a highly significant gene found
in each of the data sets (IL23R) by regressing case control
status onto SNPs located within IL23R. The residuals
from the regression were then used as the outcome vari-
able and PCA regression was used to recalculate all of the
gene scores. These gene scores and permutations of the
residuals were used in the same way described above to
calculate and estimated FDR for each method. The accu-
racy was assessed using the mean square error and per-
mutation was used to obtain the alpha 0.01 cut-off.
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status onto SNPs located within the gene.
Additional file 3 Significant pathways from Binomial analysis. The 
table lists the significant pathways across dataset (WTCCC, Jewish, non-
Jewish) and IL23R status (included, excluded, conditioned upon). An 'X' 
means the pathway had an FDR less than 0.01.
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